Pharma Journalist

Cell Therapy Potency Assay Summit
2022-07-25 - 2022-07-27 | The Bostonion, 26 North Street, Boston, MA, 02109, United States
Cell Therapy Potency Assay Summit, taking place from 25-27 of July in Boston, will bring together professionals working in analytical development, quality, regulatory and process development functions.
Join your peers to:

Brainstorm best-in-class approaches to overcome variability in QC
Compare next gen approaches from cytotoxicity to omics
Develop reference standards to benchmark across the industry
Create an assay with commercialization in mind.

This summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development.
You can view the event guide here: https://ter.li/6a13vg
Secure your place at the summit here: https://ter.li/zp17ep
We are looking forward to welcoming you to Boston this July!

LEAP HR Life Sciences East
2022-07-18 - 2022-07-20 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
LEAP HR: Life Sciences East 2022 Conference will be taking place as an in-person event in Boston, July 18-20. Returning as a physical event for its seventh year, this event will showcase 35+ case studies of how life sciences organizations of all stages and sizes are redefining post-pandemic best practices and turbocharging the employee experience to meet the holistic and previously unmet needs of your in-demand life science workforce.
This is a unique chance to take advantage of a combination of plenary sessions, breakout sessions, panels and roundtable discussions specifically designed to solve your biggest HR challenges and deliver actionable insights for HR innovation.
Network with 250+ other strategic HR leaders working within life sciences on the East Coast and surrounding areas and join a support network of 500+ life science HR leaders who have previously taken part.
You’ll hear from companies such as: Takeda, Novo Nordisk, AstraZeneca, Pfizer, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, BioNTech, Ipsen, Novartis, PTC Therapeutics, TCR2 Therapeutics, Ginkgo BioWorks and more…
Find out more by visiting the website: https://leap-hr-lifesciences-east.com/

2nd Annual Next Generation Gene Therapy Vectors Summit
2022-07-18 - 2022-07-20 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Overcome First Generation Gene Therapy Vector Challenges To Guarantee Targeted, Specific, Efficient & Safe Gene Delivery
The 2nd Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors to deliver safe and efficacious gene therapy products.
Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups are set to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
Spanning a range of delivery approaches from cutting-edge AAV capsid optimization, utilizing lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach.
Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.
To know more visit: https://ter.li/3mccj3

RNA Therapeutic Modalities Summit USA
2022-07-15 - 2022-07-16 | Boston, USA
The RNA Therapeutic Modalities Summit is North America’s only industry led conference covering clinical progress and commercial scale development for the full spectrum of RNA therapeutic approaches.
Our agenda will featuring the pioneering biotechs translating current vaccine success into further clinically validated treatments in broader indications using RNA technologies such as antisense oligonucleotides, aptamers, small interfering RNAs (siRNAs), microRNAs, and messenger RNA (mRNA).
There will be dedicated discussion on the rationale for different mechanisms-of-action, how to optimise the power and versatility of RNA-based constructs, and the progress to date in disease indications encompassing neurodegeneration, metabolic and cardiovascular disorders and various cancers.
If your R&D teams are looking to establish a differentiated drug platform through RNA modification and delivery systems, improve stability, delivery and durability of current drug candidates, or enable tissue-specific administration with higher targeting ability and less toxicity, make sure they secure a place at this hotly anticipated conference. We look forward to welcoming you to Boston for dedicated in-person networking in June!
To know more visit: https://hubs.ly/Q012R75G0

Advanced Wound Care Summit
2022-07-13 - 2022-07-14 | Boston, MA (Venue TBD)
The Advanced Wound Care Innovation Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from, and discuss with, world leaders of wound care research who are driving the development of novel biomaterials, remote-monitoring devices, and digital health management solutions.
Find out how C-level Executives, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive, investor, researcher or healthcare professional, this meeting offers an empowering environment that allows you to make wound care decisions with confidence.
To know more visit: www.advancedwoundcareusa.com

BCMA Targeted Therapies Summit
2022-07-12 - 2022-07-14 | The Bostonian, 26 North St, Boston, MA, 02109, United States
With the undeniable excitement in the BCMA field over the past few months, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline.
Pick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond.
Hear from leading speakers including:

Suzette Girgis, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies, Johnson & Johnson Services
Eric Fedyk, Global Program Leader of BCMA Assets, 2seventy bio
David DiLillo, Director, Immuno-Oncology, Regeneron
Brandon Kremer, Group Senior Medical Director, Clinical Development Lead, GlaxoSmithKline
Nathan Martin, Translational Scientist & Project Lead, Bristol Myers Squibb
Mike Damore, Director & Lead – Translational Oncology, Pfizer
Chetasi Talati, Medical Director, AbbVie
Dexiu Bu, Senior Principle Scientist, CART group, Immuno-Oncology & Hematology, Novartis
Faiza Zafar, Senior Medical Science Liaison, Legend Biotech

Take a look at the full event guide to learn more.

3rd GxP Cloud Compliance Summit
2022-07-12 - 2022-07-14 | The Bostonian, 26 North St, Boston, MA, 02109, United States
Migrate Your GxP Regulated Applications to the Cloud with Compliance, Security, & Quality Assurance
With hot anticipation for the FDA’s new CSA guidance, life science companies have the opportunity to take a proactive stance in their approach to the new methodologies. In the climate of this exciting new era of computer systems validation, join over 100 Life Science, IT & Quality professionals at the 3rd GxP Cloud Compliance Summit.
Emulating on 2021’s success, the 3rd GxP Cloud Compliance Summit is excited to return in July, for the first time in person!
This is your only opportunity to develop and implement a practical roadmap to migrate your GxP regulated applications to the cloud with real-life insights from regulatory, security and quality experts from leading life science companies, as well as cloud providers, auditors, and industry regulators.
With the FDA strongly advising life science organizations to start getting ready for CSA now, join us in July to discover how your business can get ahead and simplify the transition process.
To know more visit: https://ter.li/uichgz

Digital Biomarkers and Clinical Measures in Neurology Summit
2022-07-11 - 2022-07-13 | The Bostonian, 26 North St, Boston, MA, 02109, United States
The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data.
From integrating wearable technologies, smartphone apps, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy, join industry experts from Merck, Janssen, GSK, Sanofi, Novartis, Takeda, Eli Lilly & Company, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets.
To know more visit: https://ter.li/mk4lmh

3rd Annual Gene Therapy for Neurological Disorders Europe
2022-07-11 - 2022-07-13 | Paris Marriott Charles de Gaulle Airport Hotel, Zone Hoteliere, 5 All. du Verger, Roissy-en-France, 95700
Accelerating Europe’s Progress in CNS Gene Therapy
Navigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic
As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders.
Returning as its first in-person meeting, with brand new speakers and companies joining the conversation, attend alongside 100 fellow preclinical, translational, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target, and optimize your European strategy as you move from rare to common patient populations.
To know more visit: https://ter.li/l4b1t3

Microbiome Connect: Europe
2022-07-06 - 2022-07-07 | Amsterdam
The 8th Annual Microbiome Connect: Europe 2022 dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.
As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have to opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.
Furthermore, there will be separate tracks dedicated to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skincare applications.
Join the microbiome field to hear from biotechs, pharma voices, investment bodies, consumer product brands and more, on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.
To know more visit: https://hubs.ly/Q012R7H40

11th Annual HPAPI Summit
2022-06-28 - 2022-06-30 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Undoubtedly, the past two years have changed the pharma industry forever; new modalities are dominating pharma pipelines, drugs are increasing in potency, and the restrictions around product quality are tighter than ever before.
It is integral that the HPAPI community comes together to apply expertise in ensuring operator safety, alongside product quality, to the future of hazardous drug production and fully understand this new landscape, and regulatory environment. Built in collaboration with industry experts, the HPAPI Summit provides end-to end coverage tackling; development, commercial manufacturing & tech transfer, occupational toxicology, industrial hygiene & EHS, across small molecules, large molecules, drug conjugates & ATMP, for a holistic approach to bullet-proofing your hazardous drug production.
With sessions championed from the likes of Merck, Bayer, AstraZeneca, Takeda and more, don’t miss this opportunity to reconnect, reassess and re-enforce your risk management for your potent pipeline and production at the longest standing and largest global summit for highly potent API’s & hazardous drugs.
Save up to $700 on your event pass when you book before Friday, May 20.
Group discounts of up to 20% are also available when you bring your team!
To know more visit: https://ter.li/3csco9

3rd TCR-based Therapies for Solid Tumors Summit
2022-06-27 - 2022-06-29 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Are you using TCRs to target solid tumors yet?
With Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail, 2022 is fast becoming the year for TCRs.
Join the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies.
Featuring 24+ expert speakers, over 80% of whom are new for 2022, this summit will address the toughest challenges in TCR development, such as improving TCR discovery and efficacy, combating the tumor microenvironment, optimizing target selection and advancing manufacturing, preclinical and clinical processes.
Join leaders in the field, including Adaptimmune, Iovance and TScan as they examine methods to prevent cross reactivity, increase cell fitness and infiltration, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need.
Find out more in the Event Guide: https://ter.li/sa0pnw

Non-Viral RNA Delivery Systems Summit
2022-06-21 - 2022-06-23 | The Bostonian, 26 North St, Boston, MA, 02109, United States
Built with biopharmaceutical industry insights, this in-person conference will delve into the latest advancements of non-viral RNA delivery systems such as LNPs, exosomes and polymers to set the scene for the translation of targeted, safe and durable delivery systems for RNA therapeutics and vaccines with improved formulation, distribution and tissue-specificity.
Don’t miss 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia who are shaping the landscape of advanced and emerging non-viral RNA delivery systems for the RNA biopharma community worldwide.
Join this meeting to hear cutting-edge science and latest data on:

Expand Therapeutic Applications with Emerging Non-Viral RNA Delivery Systems
Discover Novel LNP & Alternative Technologies to Increase Specificity & Efficacy
Learn About the Latest Improvements of Non-Viral Delivery Systems for the Delivery of a Broad Range of RNA Payloads
Increase Tissue Specific & Extrahepatic Delivery through Optimizing Formulation & Design
Delve into the emerging Engineering, Formulation & Packaging Methods to Improve Non- Viral RNA Delivery & Stability

Join 80+ VPs, Heads and Directors of RNA delivery, Formulation and Process development for a deep dive into delivery challenges and strategies of non-viral systems to fully unleash the therapeutic opportunities offered by different RNA therapeutics and vaccines.
To know more visit: https://ter.li/ai0qwx

7th Microbiome Movement - Drug Development Summit
2022-06-21 - 2022-06-23 | Revere Boston Common, 200 Stuart St, Boston, MA, 02116, United States
The 7th Microbiome Movement – Drug Development Summit returns to Boston at a pivotal time. As the microbiome therapeutic space matures, with more indications being pursued and more companies conducting trials, the focus of this event – now in its 7th year – is evolving to showcase these new studies. With this progress however comes new challenges, and we’re excited to once again be uniting over 300 microbiome pioneers to work towards overcoming these challenges and moving the whole industry closer to commercial approval.
Continuing to unite the most forward-thinking researchers from the biopharmaceutical industry, our unrivaled program will uncover microbiome functionality and mechanisms, decipher translation issues and advance clinical development, overcome the key GMP manufacturing and scale-up challenges, whilst also discovering and applying microbiome biomarkers for improved clinical outcomes.
This event is the most comprehensive forum for microbiome drug developers and the perfect opportunity for the industry to take a collaborative approach to close the clinical gap, discover the next generation of microbiome-based therapeutics, and establish new partnerships to accelerate your research.
To know more visit: https://bit.ly/3hss4dD

CPhI & P-MEC China 2022
2022-06-21 - 2022-06-23 | SNIEC, Shanghai, China
CPhI & P-MEC China is Asia’s leading pharmaceutical show for trading, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPhI & P-MEC China 2022, with the co-located shows FDF, bioLIVE, Pharma Excipients, NEX and LABWORLD China, etc. is expected to draw near 3,000 exhibitors and hundreds and thousands of professionals from the pharmaceutical industry.
To know more visit: https://bit.ly/3n5sp8w

2nd Inner Ear Disorders Therapeutics Summit
2022-06-20 - 2022-06-21 | The Bostonian, 26 North St, Boston, MA, 02109, United States
Biotech companies are paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. The field is booming with excitement, with pharma companies increasing investment into these pipelines in the race to successfully reverse hearing damage.

Returning as an in-person event to Boston, the 2nd Inner Ear Disorders Therapeutics Summit will unite drug developers focusing on preventative and regenerative approaches targeting the inner ear.
Debate the clinical applicability of different modalities, including small molecule, stem cell and gene therapy; accurately monitor hearing loss progress, successfully identify new targets, optimize preclinical models, discuss combination strategies for drugs and devices and hear the latest clinical updates and novel translatable research of the inner ear.
Join over 100 drug developers from the likes of Otonomy, Sound Pharmaceuticals, Frequency Therapeutics, Astellas, Sensorion, Decibel Therapeutics and more at this 4-day disease-agnostic, modality-agnostic event designed specifically for industry-based experts in inner ear disorders to successfully translate their therapeutics into the clinic.
To know more visit: https://ter.li/1wvymk

2nd Tumor Myeloid-Directed Therapies Summit
2022-06-14 - 2022-06-16 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Returning in 2022, the 2nd Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.
This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function.
Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development.
If you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment
Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more
With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.
To know more visit: https://ter.li/2067lj

2nd HER2-Targeted Therapies Summit
2022-06-14 - 2022-06-16 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 ‘low’ space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before.
As such, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma, biotech and academia to unite under one roof to discuss these developments, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients.
As the clinical and commercial opportunity of HER2-targeted therapies becomes apparent, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target.
View the full agenda now: https://ter.li/kxq80g

Pre Filled Syringes West Coast
2022-06-13 - 2022-06-14 | San Diego, CA, USA
SMi’s 6th Annual Conference
Pre-Filled Syringes West Coast
June 13 – 14, 2022 | San Diego, CA, USA
SESSING DEVICE DEVELOPMENT AND REGULATION FOR ADVANCED INNOVATION
SMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference, to be held in San Diego. As part of SMi’s leading series of drug delivery device conferences, the 2022 event will provide insights into the rapidly accelerating market of combination product development with industry, device developer and regulatory perspectives.

The last year has seen major advances in device design and development with patient usability, ease of use and safety remaining at the forefront. This upcoming conference will assess the industry movement towards enabling self-administration through advanced device design, innovations in connectivity to aid the user, and the increasing importance of biologics and novel drug product considerations for device development. Furthermore, regulatory bodies and leaders from big pharma will give an international update on the fast-evolving industry landscape. As one of our most sought-after events, this conference is not to be missed.
This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
Benefits of attending:

Discover the latest advances in innovative device design for user-centric drug delivery
Assess evolving approaches to platforms for advanced combination product portfolios
Uncover the key considerations to ensure optimal lifecycle management for drug delivery devices
Explore how the industry is evolving with global developments including case studies of sustainable practices for drug delivery devices and the industry’s role in mass vaccination campaigns
Engage in interactive sessions reviewing the landscape of on-body injectors for large volume delivery and the role of connectivity for wearable devices

ChAiRs foR 2022:
Tina Rees, Associate Director, Human Factors, Regeneron Pharmaceuticals
Natalie Abts, Head of Human Factors Engineering, Genentech
Featured 2022 speakers include:

Sriman Banerjee, Head of Packaging Development & Commercial Device Engineering, Takeda
Amin Sedighiamiri, Associate Director, Device Development, AstraZeneca
James Wabby, Executive Director, Head of Regulatory Strategy, Emerging Technologies and Combination Products, Abbvie
Khaudeja Bano, Executive Medical Director, Combination Product Safety Head, Amgen
Rachel poker, Associate Director, Human Factors, AstraZeneca
Kristina Li, Sr. Engineer II, Technical Development, Biogen
sujani Nannapaneni, Human Factors Principal Research Engineer, Combination Product Development, Abbvie

Who should attend?

Drug-delivery developers
Medical Device Engineers
Primary Packaging material designers
Secondary packagers
Smart device developers
Training device developers
Device-safety solution providers
Drug developers

Previous attendees include:
Abbott Laboratories; AbbVie; Advanced Molding Technologies; Aegerion Pharmaceuticals; Ajinomoto Althea, Inc.; Allergan; Allergen Inc; Almac Group; Amgen; Antares Pharma; Aptar Pharma; AstraZeneca; Baxter Healthcare; BCM Group LLC; BioMarin; Boehringer Ingelheim; Connecticut Spring & Stamping; Credence MedSystems, Inc.; Execution Metrics, Inc; Ferring Pharmaceuticals; Fresenius-Kabi; Genentech; Genentech, Inc.; Gilead Sciences; Glenmark Pharmaceuticals; Harro Hofliger Verpackungsmaschinen GmbH; Inovio Pharmaceuticals; iO Lifesciences; Ionis Pharmaceuticals; Ionis Pharmaceuticals, Inc.; Matchstick; MedImmune; MedImmune LLC; Medizap; Medtronic; Merck & Co.; Mitsubishi Gas Chemical Company, Inc; Nemera; Nipro PharmaPackaging; NOVO Engineering, Inc.; Novo Nordisk; Novo Nordisk A/S; One World DMG; Owen Mumford; Pfenex; Pfenex Inc; Pfizer CentreOne; RAUMEDIC INC; Regeneron; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Shire; Smithers Rapra; Steri-Tek; Stevanato Group S.p.A; Subcuject ApS; Suttons Creek Inc; Terumo Corporation; Terumo Medical Corporation; Terumo Pharmaceutical Solutions; UserWise, Inc.; W. L. Gore & Associates, Inc.; West Pharmaceutical Services; West Pharmaceutical Services,; West Pharmaceuticals Services Inc; Worrell; Xeris Pharmaceuticals; ZebraSCI; zebrasci inc; ZEON CORPORATION; Zeon Specialty Materials ; Zeon Specialty Materials Inc
Find out more here: http://www.prefilled-syringes-westcoast.com/
SMi Group offer direct access to key decision makers through tailored sponsorship, exhibitor and delegate packages. For details contact Daniele Moreschi on +44 7498539226
Additional Contact Info:
T: +44 (0)20 7827 6088
E: rjones@smi-online.co.uk
Follow us: @SMiPharm #SMiPFSUSA

2nd Annual Gene Therapy Patient Engagement Summit
2022-06-07 - 2022-06-09 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Integrate the Patient Voice to Develop Safer & More Effective Gene Therapies That Are Meaningful to Patients

As investment in gene therapies continues to grow rapidly, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs.
In this context, the 2nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement, generating actionable insights through detailed case studies and open, honest discussions.
Join us to hear directly from companies and institutions including Spark Therapeutics, Ultragenyx, FDA, Global Genes, and CRISPR Therapeutics on key topics including managing expectations across gene therapy development, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations. Leverage their knowledge and experiences to ultimately ensure effective creation and implementation of patient-centric gene therapy programs.
To know more visit: https://ter.li/c9d6sy

3rd Annual Gene Therapy Analytical Development Europe
2022-05-30 - 2022-06-01 | Victoria Park Plaza Hotel, 239 Vauxhall Bridge Road, Pimlico, London, SW1V 1EQ, United Kingdom
Uncover the Robust Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products
In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products.
Whether you’re looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand.
Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.
To know more visit: https://ter.li/04rwmv

ADC Analytical Development Summit
2022-05-25 - 2022-05-27 | Hyatt Regency Boston Cambridge, 575 Memorial Drive, Cambridge, MA, 02139, United States
As ADCs continue to see clinical success, and as drug design becomes more complex, regulatory scrutiny to ensure product quality is increasing. The trailblazing ADC Analytical Development Summit is the first and only industry focused meeting dedicated to addressing the unique challenges faced by analytical, CMC, QC, process development and protein characterization experts working on ADCs.
Covering the end-to-end development and application of analytical technologies in a phase-dependent manner, this novel meeting will focus on enhancing ADC characterization, understanding drug potency and demonstrating homogeneity to support regulatory requirements.
With the sharing of unique insights into novel method development, CQAs, bioassays, DAR quantification and distribution, and platform approaches, this is your unmissable opportunity to get up to speed with this rapidly growing field and to support safe, consistent and high quality ADC development.
Through a series of in-depth case studies, interactive panel discussions and roundtables, informative and enriching workshops, and networking with likeminded individuals pioneering analytical development, you’ll be equipped to advance your understanding of the safety, identity, potency, purity and quality of your ADC.
To know more visit: https://ter.li/0ay4ao

Hippo Pathway Targeted Drug Development Summit
2022-05-24 - 2022-05-26 | DoubleTree Suites by Hilton Hotel Boston, 400 Soldiers Field Road, Cambridge, Boston, MA, 02134, United States
It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Although once seen as an elusive pathway, emerging novel data and research is forging a wider and more developed mechanistic understanding of it. New avenues have been opened to evolve the landscape of targetable nodes and therapeutic interventions, from small molecule approaches to novel modalities targeting the TEAD transcription complex.
With the clear therapeutic potential of this highly attractive and targetable pathway, investment, collaboration, and interest has flooded in through biopharma and academia – and what was once an unexploited space is now seeing an abundance of promising therapeutic interventions.
The inaugural Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry dedicated forum focused on accelerating the mechanistic understanding and potential of the Hippo signaling pathway to enhance the discovery, translation, and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.
Uniting the leading minds of large pharma, biotech and academia, this unrivalled conference will showcase the pioneering discoveries, critical novel findings and promising clinical candidates drugging YAP, TAZ & TEAD transcription factors and other high-value targets within the Hippo pathway. With Keynote sessions from Ikena Oncology, Spring Works Therapeutics, Cedilla and Vivace Therapeutics, this is a unique opportunity to hear first-hand the development of novel YAP/TAZ-TEAD antagonists, from discovery to the clinic.
Over 80 key stakeholders from BridgeBio, Cancer Research UK, AstraZeneca, Orion Pharma, Faze Medicines, Inventiva, Zentalis Pharmaceuticals, Basilea Pharmaceuticals and many more have already confirmed their places as the industry continues to unlock critical pieces of the puzzle in the understanding and exploitation of this signaling pathway.
Together, we will unite to learn, debate, and discuss; leverage the therapeutic opportunity of this pathway; and critically address the huge unmet clinical need.
To know more visit: https://ter.li/4tdp3b

4th Annual Cell Engager Summit
2022-05-24 - 2022-05-26 | Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
4th Annual Cell Engager Summit May 24-26, 2022 | Boston, MA

The 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies, including CD19, CD20, BCMA, CD33, and CD123.

This must-attend meeting will provide a comprehensive understanding of the development of multi-specific cell engaging therapeutics in liquid and solid tumor indications, with the goal of bringing early-stage innovation to the clinic.
Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries.
You will leave this meeting with key steps to improving safety and efficacy in the solid tumor microenvironment through lower CRS, greater dose, and lower TMDD by targeting tumor antigens such as HER2 and EGFR, and modifying co-stimulatory receptors (for example CD137/4-1BB, CD28).
Ensure your Cell Engager program reaches full clinical potential through learning from the pioneers of immunotherapy.
To know more visit: https://ter.li/d3i1x0

Next Generation RNA Therapeutics Summit
2022-05-24 - 2022-05-26 | Omni Parker House, 60 School St, Boston, MA, 02108, United States
With novel RNA-based modalities having seen extraordinary development in the last 18 months, there has never been a more important time for the RNA community to unite, share learnings and accelerate the field towards successful proof of concept and effective therapeutic development.
Stay ahead of the curve with novel RNA therapeutics and vaccines that offer exceptional stability and durability whilst addressing key delivery, pharmacology and scalability challenges to successfully translate safe and effective next generation RNA therapeutics into the clinic.
The Next Generation RNA Therapeutics Summit is the only meeting to deep dive into the specific challenges and opportunities associated with novel RNA modalities, welcoming cutting-edge biotech giants such as Pfizer, BioNTech, Moderna Therapeutics and Replicate Bioscience to share unmissable insights on circular RNA, tRNA and self-amplifying RNA therapeutics and vaccines.
Join 80+ thought leaders under one roof as they set the scene for next generation RNA therapeutics. This unique group of Directors, Heads and VPs of RNA Therapeutics, Chemistry, Delivery and New Therapeutics will unite at this must-attend event for the RNA community. Don’t miss out!
To find out more, visit: https://ter.li/0ei6ql

Customer Engagement Europe 2022
2022-05-24 - 2022-05-25 | Hilton Tower Bridge, London 5 More London Riverside, Tooley St, London, SE1 2BY, United Kingdom
Precise, Personalized and Proactive- the future of customer engagement is a digitally enabled, hybrid omnichannel strategy.
Heard that all before?

From measuring clicks to measuring behaviour change, the way we think about customer preference has forever been changed. Across marketing, commercial, and medical, the skills we need to deliver on changing HCP expectations are aligning. Now is the time to do the same for our strategy.
Reuters Events Pharma: Customer Engagement Europe 2022 (London, May 24-25) is the only pharma event bringing together functions to drive the future of agile engagement. Join us to deliver a hybrid, insight driven, modularized model that incorporates iterative insights, delves deeper into data, empowers our field forces with digital empathy, prioritizes innovation, and equips our teams for industry leadership.
To know more visit: https://bit.ly/3qz6d9B

Customer Engagement Europe 2022
2022-05-24 - 2022-05-25 | Hilton Tower Bridge, London 5 More London Riverside, Tooley St, London, SE1 2BY, United Kingdom
Deliver enduring behavioral change with agile, personalized engagement
Precise, Personalized and Proactive- the future of customer engagement is a digitally enabled, hybrid omnichannel strategy.
Heard that all before?
From measuring clicks to measuring behaviour change, the way we think about customer preference has forever been changed. Across marketing, commercial, and medical, the skills we need to deliver on changing HCP expectations are aligning. Now is the time to do the same for our strategy.
Reuters Events Pharma: Customer Engagement Europe 2022 (London, May 24-25) is the only pharma event bringing together functions to drive the future of agile engagement. Join us to deliver a hybrid, insight driven, modularized model that incorporates iterative insights, delves deeper into data, empowers our field forces with digital empathy, prioritizes innovation, and equips our teams for industry leadership.
To know more visit: https://events.reutersevents.com/pharma/customer-engagement-europe

Medical Device Software Development Summit 2022
2022-05-17 - 2022-05-19 | DoubleTree by Hilton Hotel Boston, North Shore, 50 Ferncroft Rd, Danvers, MA, 01923, United States
Bringing together a senior audience of cutting-edge device manufacturers, and featuring a unique program focused on real-life use cases, the 2022 Medical Device Software Development Summit offers you a toolkit for designing compliant, innovative, and secure medical device software, enabling you to move one step ahead of emerging trends.
So whether you’re a part of a regulatory, quality, or technical team, join the Medical Device Software Development Summit to meet like-minded peers who are pioneering new technologies and methodologies to develop innovative medical device software, ultimately bringing value to patients.
5 key topics at Medical Device Software Development Summit

Navigate Regulations when Behind Innovation
Continue to push the boundaries of innovation with AI-enabled medical devices
Understand and implement agile software development methodologies
Implement risk analysis into the software development lifecycle
Focus your attention on device security to avoid breaches

To find out how you and your team can get involved download your free event guide or get in touch.

4th Treg Directed Therapies Summit
2022-05-17 - 2022-05-19 | Embassy Suites by Hilton, Boston Logan Airport 207 Porter St, Boston, MA, 02128, United States
As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy.
The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non cell-based Treg directed therapies to provide efficacious treatments for patients globally.
With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimizing early drug development, and streamlining clinical development, join with your team to:

Optimize stable expansion of Tregs to maintain function to elicit durable responses
Decode Treg interactions to optimize the mechanism of actions and inform biomarker development
Rationalize activation, formulation & delivery strategy to induce antigen specific tolerance
Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy

200+ senior level drug developers will be uniting in May to chase the holy grail of Treg-directed therapies. Don’t miss your chance to network with the avant-garde to inform your Treg pipeline and capitalize on the shared knowledge of this collaborative community.
To know more visit: https://ter.li/fhrzm3

Pharma Clinical 2022
2022-05-17 - 2022-05-19 | Virtual
The pandemic response has accelerated technology adoption in clinical trials, but we have neglected patient needs by failing to develop co-created, data-driven, standardised and accountable trial designs.
In the face of rethinking clinical strategy, our mission is clear: it’s time to develop a better system. We must establish new industry-wide benchmarks now, leverage recent digital innovations, and ensure permanent cultural change toward patient- centric trials. If we do not act immediately, we risk losing this opportunity to rebuild patient trust.
This is why we are bringing together the world’s clinical leadership at Reuters Events: Pharma Clinical 2022 (May 17-19, Virtual). We aim to define the new standards in digital and patient innovation for clinical transformation. Join 500 + clinical innovators and 40 + expert speakers to create an accountable clinical ecosystem where patient diversity, centricity and empowerment aren’t just slogans – they are core principles.
To know more visit: https://bit.ly/3npeUkP
